Interaction Between Reboxetine and 3,4-Methylenedioxymethamphetamine: Pharmacodynamics (PD) and Pharmacokinetics (PK)
Information source: University Hospital, Basel, Switzerland
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Mood Disorder; Substance-related Disorders; Amphetamine-related Disorders
Intervention: MDMA (Drug); Reboxetine, 8 mg (Drug); Placebo (Drug)
Phase: Phase 1
Status: Completed
Sponsored by: University Hospital, Basel, Switzerland Official(s) and/or principal investigator(s): Matthias E Liechti, MD, Principal Investigator, Affiliation: Department of Internal Medicine, Division of Pharmacology & Toxicology, University Hospital Basel, Switzerland
Summary
MDMA releases dopamine, serotonin, and norepinephrine in the brain. Serotonin uptake
inhibitors have been shown to interact with 3,4-Methylenedioxymethamphetamine (MDMA) and to
decrease its psychoactive and cardiovascular stimulant effects. This finding indicates that
MDMA acts in part by releasing serotonin through the serotonin uptake site. However, in
vitro studies show that MDMA binds more potently to the norepinephrine uptake site that to
the the serotonin or dopamine uptake transporter. In addition, norepinephrine uptake site
blockers such antidepressant drugs attenuate some of the behavioral effects of MDMA in
animals. These preclinical data indicate that norepinephrine may also contribute to the
response to MDMA in humans. To test this hypothesis this study evaluates the interacting
effects of the selective norepinephrine transporter inhibitor reboxetine on the subjective
and cardiovascular stimulant effects of MDMA in healthy volunteers.
Clinical Details
Official title: Pharmacological Interaction Between Reboxetine and 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy): Pharmacological Effects and Pharmacokinetics
Study design: Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science
Primary outcome: Effect of reboxetine on subjective responses to MDMA
Secondary outcome: Effect of reboxetine on physiological responses to MDMAEffects of reboxetine on pharmacokinetics of MDMA Tolerability of MDMA and reboxetine Effect of reboxetine on neuroendocrine responses to MDMA
Detailed description:
The study will use a randomized double-blind cross-over design with four experimental
sessions. Reboxetine (8 mg) or placebo will be administered the night before the
experimental session and 1 h before the administration of MDMA (125 mg) or placebo to 16
healthy volunteers. Subjective and cardiovascular responses and plasma samples for
pharmacokinetics will be repeatedly assessed throughout the experiments.
We hypothesize that the highly selective norepinephrine uptake inhibitor reboxetine will
attenuate subjective and especially heart rate and blood pressure responses to MDMA. Such a
result would indicate that norepinephrine is critically involved in the pharmacology of MDMA
and may provide helpful in the use and development of treatments for Ecstasy intoxications.
Eligibility
Minimum age: 18 Years.
Maximum age: 45 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Sufficient understanding of the German language
- Subjects understand the procedures and the risks associated with the study
- Participants must be willing to adhere to the protocol and sign the consent form
- Participants must be willing to refrain from taking illicit psychoactive substances
during the study.
- Participants must be willing to drink only alcohol-free liquids and no
xanthine-containing liquids (such as coffee, black or green tea, red bull, chocolate)
after midnight of the evening before the study session. Subjects must agree not to
smoke tobacco for 1 h before and 4 hours after MDMA administration.
- Participants must be willing not to drive a traffic vehicle in the evening of the
study day.
- Women of childbearing potential must have a negative pregnancy test at the beginning
of the study and must agree to use an effective form of birth control. Pregnancy
tests are repeated before each study session.
- Body mass index: 18-25 kg/m2
Exclusion Criteria:
- Chronic or acute medical condition including clinically relevant abnormality in
physical exam, laboratory values, or ECG. In particular: Hypertension (>140/90 mmHg).
Personal or first-grade history of seizures. Cardiac or neurological disorder.
- Current or previous psychotic or affective disorder
- Psychotic or affective disorder in first-degree relatives
- Prior illicit drug use (except Tetrahydrocannabinol-containing products) more than 5
times or any time within the previous 2 months.
- Pregnant or nursing women.
- Participation in another clinical trial (currently or within the last 30 days)
- Use of medications that are contraindicated or otherwise interfere with the effects
of the study medications (monoamine oxidase inhibitors, antidepressants, sedatives
etc.)
Locations and Contacts
University Hospital, Basel, Switzerland
Additional Information
Starting date: April 2009
Last updated: January 24, 2013
|